Adell Harriman & Carpenter Inc. cut its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 15.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 3,123 shares of the exchange traded fund’s stock after selling 584 shares during the quarter. Adell Harriman & Carpenter Inc.’s holdings in SPDR S&P Biotech ETF were worth $279,000 as of its most recent filing with the SEC.
Several other large investors have also bought and sold shares of XBI. Commonwealth Equity Services LLC raised its position in SPDR S&P Biotech ETF by 58.1% during the third quarter. Commonwealth Equity Services LLC now owns 195,033 shares of the exchange traded fund’s stock valued at $14,241,000 after buying an additional 71,658 shares during the period. Compagnie Lombard Odier SCmA raised its position in shares of SPDR S&P Biotech ETF by 417.4% during the third quarter. Compagnie Lombard Odier SCmA now owns 2,975 shares of the exchange traded fund’s stock valued at $217,000 after buying an additional 2,400 shares during the last quarter. Sheets Smith Wealth Management bought a new position in SPDR S&P Biotech ETF in the third quarter worth $55,000. Deltec Asset Management LLC increased its holdings in SPDR S&P Biotech ETF by 28.4% in the 3rd quarter. Deltec Asset Management LLC now owns 36,200 shares of the exchange traded fund’s stock valued at $2,643,000 after buying an additional 8,000 shares during the period. Finally, AFG Fiduciary Services Limited Partnership raised its stake in shares of SPDR S&P Biotech ETF by 12.5% in the 3rd quarter. AFG Fiduciary Services Limited Partnership now owns 9,171 shares of the exchange traded fund’s stock valued at $638,000 after buying an additional 1,019 shares in the last quarter.
SPDR S&P Biotech ETF Stock Down 0.6 %
NYSEARCA:XBI traded down $0.48 during trading hours on Tuesday, reaching $85.04. The company had a trading volume of 1,941,145 shares, compared to its average volume of 11,587,669. The firm has a market capitalization of $6.61 billion, a PE ratio of 11.47 and a beta of 1.08. SPDR S&P Biotech ETF has a one year low of $63.80 and a one year high of $103.52. The stock has a 50-day moving average of $92.54 and a two-hundred day moving average of $84.94.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- Pros And Cons Of Monthly Dividend Stocks
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
- How to invest in blue chip stocks
- Seagate Technology Warns Cloud Demand is Heating Up
- 5 Top Rated Dividend Stocks to Consider
- McDonald’s Trend Following Signal is an Opportunity Today
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.